<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02873390</url>
  </required_header>
  <id_info>
    <org_study_id>NBWYKY2016-06-001/002/003</org_study_id>
    <nct_id>NCT02873390</nct_id>
  </id_info>
  <brief_title>PD-1 Antibody Expressing CAR-T Cells for EGFR Family Member Positive Advanced Solid Tumor</brief_title>
  <official_title>A Clinical Study of PD-1 Antibody Expressing CAR-T Cells for EGFR Family Member Positive Advanced Solid Tumor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ningbo Cancer Hospital</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ningbo Cancer Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and effectiveness of cell therapy using herinCAR-PD1 cells to treat
      advanced cancer.

      Individuals greater than or equal to 18 years of age and less than or equal to 70 years of
      age who have been diagnosed with relapsed or refractory cancer that has not responded to or
      has relapsed after standard treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A total of 20 patients may be enrolled over a period of 1-2 years.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2016</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Anticipated">March 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Disease control rate,(DCR)</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Progress-free survival(PFS)</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>2 years</time_frame>
    <description>Questionnaire will be used.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>PD-1 Antibody</condition>
  <condition>CAR-T Cells</condition>
  <condition>Advanced Malignancies</condition>
  <arm_group>
    <arm_group_label>HerinCAR-PD1 cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive 3 cycles of HerinCAR-PD1 cells treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>HerinCAR-PD1 cells</intervention_name>
    <description>herinCAR-PD1 cells transfusion: (1-5×107/kg herinCAR-PD1 + physiological saline + 0.25% human alloalbumin) 300ml for each infusion. IV (in the vein) for each infusion, 2 cycles, each cycle received one infusions on day 21, 43.</description>
    <arm_group_label>HerinCAR-PD1 cells</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 18~80 years old, male or female;

          2. Life expectancy≥6 months;

          3. ECOG score: 0-2;

          4. Advanced Solid Tumor were diagnosed by histology and cytology;

          5. Enough venous channel,no other contraindications to the separation and collection of
             white blood cells;

          6. Immunohistochemistry and RT-PCR technology will be used to determine the positive EGFR
             family (including EGFR, HER2, HER4) and EGFRVIII、IGF1R protein. At least one protein
             expressed in immunohistochemical tumor tissue should be no less than grade 2 or 2+
             scores. The levels of protein are defined as follows: (according to cell staining) :
             grade 0: without staining; grade 1: 1-25%; grade 2: 26-50% and grade 3: 51-100%;
             (According to the intensity): negative; 1+; 2+ and 3+;

          7. Laboratory examination: white blood cell≥3 x 10*9/L, blood platelet count≥60 x10*9/L,
             hemoglobin≥85g/L; lymphocyte ≥0.7×109/L, total bilirubin less than 2.5 times of the
             normal level; ALT and AST less than 2.5 times of the normal level; serum creatinine
             less than 1.5 times of the normal level；

          8. Signed informed consent；

          9. Women of child-bearing age must have evidence of negative pregnancy test and be
             willing to practice birth control after 4 months following the cells transfusion.

         10. Disease progression and the current treatment is invalid.

         11. The treatment effect is not ideal after receiving 2 line therapy at least and willing
             to join in clinical trials

        Exclusion Criteria:

          1. Expected Overall survival ＜ 6 months;

          2. Patients with uncontrolled hypertension,unstable coronary disease (uncontrolled
             arrhythmias, unstable angina, decompensated congestive heart failure (&gt; Class II,
             NYHA), or myocardial infarction within 6 months.

          3. Abnormal lung function: FEV (forced expiratory volume) &lt; 30% prediction, DLCO
             (diffusing capacity of the lung for carbon monoxide) &lt; 30% prediction, blood oxygen
             saturation &lt; 90%;

          4. Other serious diseases: nervous, mental disorders, immune regulatory diseases,
             metabolic diseases, infectious diseases, etc;

          5. Unable or unwilling to provide informed consent, or fail to comply with the test
             requirements.

          6. Uncontrolled active infection.

          7. Serious chronic disease of critical organs such as kidney and liver. Kidney function
             more than CKD stage I,and liver function less than the Child - Pugh class B;

          8. Long-term use or being used of immunosuppressive drugs with autoimmune diseases

          9. Glucocorticoid is needed in a long term.

         10. Currently (within 30 days) enrolled in another clinical trial.

         11. Pregnancy or breastfeeding women.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jiangtao Wang</last_name>
    <role>Study Director</role>
    <affiliation>Ningbo No.5 Hospital (Ningbo Cancer Hospital)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Huajun Jin</last_name>
    <role>Study Chair</role>
    <affiliation>Shanghai Cell Therapy Research Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Qijun Qian</last_name>
    <role>Study Chair</role>
    <affiliation>Shanghai Cell Therapy Research Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bi Wang</last_name>
    <phone>86-13310088259</phone>
    <email>biwang0218@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ningbo No.5 Hospital (Ningbo Cancer Hospital)</name>
      <address>
        <city>Ningbo</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bi Wan</last_name>
      <phone>86-13310088259</phone>
      <email>biwang0218@126.com</email>
    </contact>
    <contact_backup>
      <last_name>Jiangtao Wang</last_name>
      <phone>86-15888102792</phone>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 15, 2016</study_first_submitted>
  <study_first_submitted_qc>August 16, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 19, 2016</study_first_posted>
  <last_update_submitted>October 6, 2016</last_update_submitted>
  <last_update_submitted_qc>October 6, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 7, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PD-1 Antibody</keyword>
  <keyword>CAR-T Cells</keyword>
  <keyword>EGFR family</keyword>
  <keyword>Advanced Malignancies</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

